NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,317,559 | -21.6% | 276,668 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $6,782,615 | -28.5% | 266,822 | +1.6% | 0.00% | -33.3% |
| Q1 2023 | $9,492,665 | -8.6% | 262,591 | +0.2% | 0.00% | 0.0% |
| Q4 2022 | $10,381,457 | -12.7% | 262,158 | +2.7% | 0.00% | -25.0% |
| Q3 2022 | $11,894,000 | +9.0% | 255,217 | +2.5% | 0.00% | 0.0% |
| Q2 2022 | $10,916,000 | -40.4% | 249,049 | -1.6% | 0.00% | -33.3% |
| Q1 2022 | $18,313,000 | -8.2% | 253,182 | +2.9% | 0.01% | 0.0% |
| Q4 2021 | $19,939,000 | -29.4% | 245,945 | +1.4% | 0.01% | -33.3% |
| Q3 2021 | $28,238,000 | -33.3% | 242,631 | -5.0% | 0.01% | -35.7% |
| Q2 2021 | $42,344,000 | +21.4% | 255,405 | +2.1% | 0.01% | +7.7% |
| Q1 2021 | $34,883,000 | -13.6% | 250,056 | +7.2% | 0.01% | -18.8% |
| Q4 2020 | $40,381,000 | +25.8% | 233,278 | +1.2% | 0.02% | +6.7% |
| Q3 2020 | $32,111,000 | +13.8% | 230,515 | -2.4% | 0.02% | +7.1% |
| Q2 2020 | $28,224,000 | +47.0% | 236,236 | +23.0% | 0.01% | +27.3% |
| Q1 2020 | $19,198,000 | -13.2% | 192,014 | +2.0% | 0.01% | -8.3% |
| Q4 2019 | $22,124,000 | +39.7% | 188,219 | +2.2% | 0.01% | +33.3% |
| Q3 2019 | $15,832,000 | +38.1% | 184,146 | +4.2% | 0.01% | +28.6% |
| Q2 2019 | $11,461,000 | +6.6% | 176,781 | +2.8% | 0.01% | 0.0% |
| Q1 2019 | $10,751,000 | +68.0% | 171,980 | +4.5% | 0.01% | +40.0% |
| Q4 2018 | $6,398,000 | -31.5% | 164,498 | +0.4% | 0.01% | -16.7% |
| Q3 2018 | $9,335,000 | -20.6% | 163,762 | +11.2% | 0.01% | -33.3% |
| Q2 2018 | $11,762,000 | -1.8% | 147,299 | +6.6% | 0.01% | 0.0% |
| Q1 2018 | $11,972,000 | +32.4% | 138,126 | +5.5% | 0.01% | +28.6% |
| Q4 2017 | $9,044,000 | -23.8% | 130,987 | +0.3% | 0.01% | -30.0% |
| Q3 2017 | $11,873,000 | +49.6% | 130,642 | +22.6% | 0.01% | +42.9% |
| Q2 2017 | $7,935,000 | -10.6% | 106,598 | +12.6% | 0.01% | -22.2% |
| Q1 2017 | $8,874,000 | +43.2% | 94,705 | +11.0% | 0.01% | +28.6% |
| Q4 2016 | $6,198,000 | -26.8% | 85,300 | +5.2% | 0.01% | -30.0% |
| Q3 2016 | $8,465,000 | +77.2% | 81,084 | +25.2% | 0.01% | +66.7% |
| Q2 2016 | $4,776,000 | +60.2% | 64,746 | +22.2% | 0.01% | +50.0% |
| Q1 2016 | $2,982,000 | -15.1% | 52,994 | +1.8% | 0.00% | -20.0% |
| Q4 2015 | $3,514,000 | +65.4% | 52,044 | +13.6% | 0.01% | +66.7% |
| Q3 2015 | $2,125,000 | +12.4% | 45,796 | +30.2% | 0.00% | 0.0% |
| Q2 2015 | $1,891,000 | +123.5% | 35,169 | +99.3% | 0.00% | +200.0% |
| Q1 2015 | $846,000 | +29.8% | 17,650 | +4.8% | 0.00% | 0.0% |
| Q4 2014 | $652,000 | – | 16,838 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |